Excedrin Migraine

In January 2014, a class-action lawsuit filed against Novartis Consumer Health over its marketing and pricing of Excedrin Migraine was removed to federal court. The complaint, which was originally filed in December 2013 in California state court, alleges that the company misleadingly represents Excedrin Migraine will treat migraines more effectively, and is therefore more expensive, than Excedrin Extra Strength when both medications actually contain the same amounts of the same ingredients. (Cortina et al v. Novartis Consumer Health, Inc., Case No. 14-cv-00069, S. D. CA.).

Two other class-action lawsuits have been filed against Novartis in the last two months making the same allegations, one in New Jersey and one in New York. (Yingst et al v. Novartis AG, Novartis Corporation, and Novartis Consumer Health, Inc., Case No. 13-cv-07919, D. NJ., and Anthony et al v. Novartis AG, Novartis Corporation, and Novartis Consumer Health, Inc., Case No. 14-cv-00161, E. D. NY.)

For more information about other class-action lawsuits regarding Excedrin Migraine and TINA.org’s coverage of the product, click here.

For more information about other class-action lawsuits regarding the deceptive advertising of migraine medications, click here.

 

Print Friendly, PDF & Email

Tags: ,



Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker



  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect TINA.org’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates